Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2013 1
2014 1
2020 1
2021 1
2022 1
2024 1
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy: Exploratory Insights From the ODYSSEY-HCM Trial.
Desai MY, Okushi Y, Jadam S, Olivotto I, Owens A, Nissen SE, Popovic ZB, Garcia-Pavia P, Lopes RD, Elliott PM, Fernandes F, Geske JB, Maier L, Wolski K, Wang Q, Jaber W, Gong Z, Florea V, Fronheiser M, Leva A, Aronson R, Abraham T; ODYSSEY-HCM Investigators. Desai MY, et al. J Am Coll Cardiol. 2025 Aug 25:S0735-1097(25)07460-1. doi: 10.1016/j.jacc.2025.08.019. Online ahead of print. J Am Coll Cardiol. 2025. PMID: 40864019
Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis.
Rettl R, Duca F, Kronberger C, Binder C, Willixhofer R, Ermolaev N, Poledniczek M, Hofer F, Nitsche C, Hengstenberg C, Eslam RB, Kastner J, Bergler-Klein J, Hacker M, Calabretta R, Kammerlander AA. Rettl R, et al. Among authors: eslam rb. Eur Heart J Cardiovasc Imaging. 2025 Jan 31;26(2):251-260. doi: 10.1093/ehjci/jeae295. Eur Heart J Cardiovasc Imaging. 2025. PMID: 39545930 Free PMC article.
His108Arg Transthyretin Amyloidosis-Shedding Light on a Distinctively Malignant Variant.
Binder C, Schmid LM, Kronberger C, Poledniczek M, Rettl R, Schlein J, Ermolaev N, Ligios LC, Auer-Grumbach M, Hengstenberg C, Eslam RB, Kastner J, Bergler-Klein J, Kammerlander AA, Duca F. Binder C, et al. Among authors: eslam rb. J Clin Med. 2024 Dec 23;13(24):7857. doi: 10.3390/jcm13247857. J Clin Med. 2024. PMID: 39768780 Free PMC article.
Renin Feedback Is an Independent Predictor of Outcome in HFpEF.
Binder C, Poglitsch M, Duca F, Rettl R, Dachs TM, Dalos D, Schrutka L, Seirer B, Ligios LC, Capelle C, Eslam RB, Qin H, Hengstenberg C, Bonderman D. Binder C, et al. Among authors: eslam rb. J Pers Med. 2021 May 3;11(5):370. doi: 10.3390/jpm11050370. J Pers Med. 2021. PMID: 34063595 Free PMC article.
Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy.
Rettl R, Mann C, Duca F, Dachs TM, Binder C, Ligios LC, Schrutka L, Dalos D, Koschutnik M, Donà C, Kammerlander A, Beitzke D, Loewe C, Charwat-Resl S, Hengstenberg C, Kastner J, Eslam RB, Bonderman D. Rettl R, et al. Among authors: eslam rb. Eur Heart J Cardiovasc Imaging. 2022 Jun 1;23(6):767-780. doi: 10.1093/ehjci/jeab226. Eur Heart J Cardiovasc Imaging. 2022. PMID: 34788394
Impact of disease-modifying therapy on [99mTc]Tc-DPD SPECT/CT markers in transthyretin cardiac amyloidosis enabled by artificial intelligence.
Spielvogel CP, Köfler M, Jiang Z, Ning J, Yu J, Haberl D, Kronberger C, Poledniczek M, Schmid LM, Kersting D, Ermolaev N, Eslam RB, Auer-Grumbach M, Binder C, Duca F, Nitsche C, Kastner J, Bergler-Klein J, Kammerlander AA, Hengstenberg C, Hacker M, Calabretta R, Rettl R. Spielvogel CP, et al. Among authors: eslam rb. Eur J Nucl Med Mol Imaging. 2025 Nov 29. doi: 10.1007/s00259-025-07673-6. Online ahead of print. Eur J Nucl Med Mol Imaging. 2025. PMID: 41317182
12 results